COMPARISON OF OPPORTUNITIES FROM TWO THERAPEUTICAL COMPLEXES FOR CORRECTION OF VASCULAR HEMOSTASIS IN HYPERTENSIVES WITH METABOLIC SYNDROME

Though there is a progress in medical science and practice, hypertension remains widely prevalent in economically developed countries, and is comorbid with metabolic syndrome. This leads to weakening of vascular wall functioning in these patients and developing conditions for the formation of intravascular thrombi of various location.

Aim. Comparative assessment of hemostatic function correction of vessel wall in hypertensives with metabolic syndrome (MS) with the complex of valsartan and losartan together with metformin and nonmedication treatments.

Material and methods. Under follow-up, there were 47 hypertensives, of 1-2 grade, risk 4, middle age. Controls were 25 healthy persons of the same age. The assessment of biochemical and hematological parameters was performed. For blood pressure correction, 24 patients were prescribed valsartan 160 mg daily, 23 patients — losartan 100 mg daily. For metabolism optimization all patients were prescribed metformin 500 mg b.i.d., hypocaloric diet and regular physical activity of tolerable intensity.

Results. The application of a complex with valsartan leads to normalization in hypertensives with MS the function of vascular wall in 4 months. Further non-strict adherence to the prescribed nonmedication part of the complex retains positive effect by the end of follow-up (12 months). Usage of losartan improves, but does not normalize vessel wall function in 4 months. Further non-strict adherence of non-medication part of treatment, regardless the continuation of losartan and metformin intake, decreases the achieved effect of treatment.

Conclusion. Usage of treatment complex of hypocaloric diet, physical exercise and metformin helps to influence positively vascular hemostasis in hypertensives with MS in case of valsartan inclusion, and is less effective if replaced by losartan.

1. Pierdomenico S, Pierdomenico A, Cuccurullo F. Meta-analysis of the relation of echocardiographic epicardial adipose tissue thickness and the metabolic syndrome. Am J Pierdomenico S. Cardiol 2013; 111(1): 73-8.

2. Mancia G. Metabolic syndrome. Hypertension 2008; 50: 32-40.

3. Dzherieva IS, Volkova NI. Hypertension and metabolic syndrome. Klinicheskaia meditsina 2010; 88(2):4-8. Russian (Джериева И.С., Волкова Н.И. Артериальная гипертензия и метаболический синдром. Клиническая медицина 2010; 88(2): 4-8).

4. Cuspidi C, Sala С, Zanchetti А. Metabolic syndrome and target organ damage: role of blood pressure. Expert Rev Cardiovasc Ther 2008; 6(5): 731-43.

5. Chumakova GA, Veselovskaja NG, Gricenko OV. Metabolic syndrome: complex and unresolved issues. Russian Journal of Cardiology 2014; 3: 63-71. Russian (Чумакова Г.А., Веселовская Н. Г., Гриценко О.В. Метаболический синдром: сложные и нерешенные проблемы. Российский кардиологический журнал 2014; 3: 63-71).

6. Medvedev IN, Gromnatskiy NI, Volobuev IV, et al. Correction of thrombocyte-vascular hemostasis in metabolic syndrome. Klinicheskaia meditsina 2006; 84(1): 46-9. Russian (Медведев И.П., Громнацкий Н.И., Волобуев И.В. и др. Коррекция тромбоцитарно-сосудистого гемостаза при метаболическом синдроме.

7. Клиническая медицина 2006; 84(1): 46-9).

8. Simonenko VB, Medvedev IN, Mezentseva NI, Tolmachev VV. The antiaggregation activity of the vascular wall in patients suffering from arterial hypertension with metabolic syndrome. Klinicheskaia meditsina 2007; 85(7): 28-30. Russian (Симоненко В.Б., Медведев И. Н., Мезенцева Н. И., Толмачев В.В. Антиагрегационная активность сосудистой стенки у больных артериальной гипертонией при метаболическом синдроме. Клиническая медицина 2007; 85(7): 28-30).

9. Simonenko VB, Medvedev IN, Tolmachev VV. Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan. Klinicheskaia meditsina 2011; 89(3): 35-8. (Симоненко В.Б., Медведев И.Н., Толмачев В.В. Динамика активности первичного гемостаза у больных артериальной гипертонией при метаболическом синдроме на фоне лечения кандесартаном. Клиническая медицина 2011; 89(3): 35-8).

10. Gromnatskiy NI, Medvedev IN. Non-pharmacological correction of impaired platelet hemostasis in hypertensive patients with metabolic syndrome. Klinicheskaia meditsina 2003; 81(4): 31-4. Russian (Громнацкий Н.И., Медведев И.Н. Коррекция нарушений тромбоцитарного гемостаза немедикаментозными средствами у больных артериальной гипертонией с метаболическим синдромом. Клиническая медицина 2003; 81(4): 31-4).

11. Volchegorskiy IA, Dolgushin II, Kolesnikov OL, Tseilikman VE. Experimental modeling and laboratory evaluation of adaptive reactions of the organism. Chelyabinsk 2000; 167р. Russian (Волчегорский И.А., Долгушин И.И., Колесников О. Л., Цейликман В.Э. Экспериментальное моделирование и лабораторная оценка адаптивных реакций организма. Челябинск 2000; 167с).

12. Barkagan ZS, Momot AP. Diagnosis and therapy controlled hemostasis disorders. Moscow: Publishing House “Nyudiamed” 2008; 292р. Russian (Баркаган З.С.,

13. Момот А.П. Диагностика и контролируемая терапия нарушений гемостаза. М: изд-во “Ньюдиамед” 2008; 292с).

14. Medvedev IN, Savchenko AP, Zavalishina SYu, et al. Methodology of blood rheology assessment in various clinical situations. Russian Journal of Cardiology 2009; 5: 42-5. Russian (Медведев И.Н., Савченко А.П., Завалишина С.Ю. и др. Методические подходы к исследованию реологических свойств крови при различных состояниях. Российский кардиологический журнал 2009; 5: 42-5).

15. Simonenko VB, Medvedev IN, Kumova TA. Pathogenetic aspects of hypertension in case of metabolic syndrome. Voenno-meditsinskii zhurnal 2010; 331(9): 41-4. Russian (Симоненко В.Б., Медведев И. Н., Кумова Т.В. Патогенетические аспекты артериальной гипертонии при метаболическом синдроме. Военно- медицинский журнал 2010; 331(9): 41-4).

16. Kutafinа NV, Zavalishina SYu. The mechanisms of functioning of the vascular-platelet hemostasis. Bulletin of Russian Peoples’ Friendship University, series “Ecology and life safety” 2012; 1: 30-7. Russian (Кутафина Н.В., Завалишина С.Ю. Механизмы функционирования сосудисто-тромбоцитарного гемостаза. Вестник РУДН, серия “Экология и безопасность жизнедеятельности” 2012; 1: 30-7).

17. Roberson LL, Aneni EC, Maziak W. Beyond BMI: The “Metabolically healthy obese” phenotype; its association with clinical/subclinical cardiovascular disease and allcause mortality — a systematic review. BMC Public Health 2014; 8(14-1): 14.